Liz Barrett wasn’t looking for a job in biotech when she got the call from a corporate headhunter she knew well. The timing was terrible — just into a new job as head of Novartis’ global, $14 billion oncology group under a new CEO looking to push a longterm change in culture.

That’s a big deal. And she had moved over from the head role at Pfizer oncology, another Big Pharma with a major mission in oncology.

There was also one other problem: She didn’t know the company. What was UroGen Pharma about? And while she knew of executive chairman Arie Belldegrun, who led Kite to a $12 billion buyout, she had never met him before.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

Nick Galakatos and his team at Blackstone Life Sciences have seen their biggest opportunities swell up in mostly established players who don’t have all the money they need to accomplish everything on the to-do list. And right now, with the industry booming, that’s a long list with some hefty needs.

The Blackstone team has neatly tied up the largest private fund ever raised in life sciences for making big dreams come true in biopharma. Late Thursday, Blackstone put out word that they had closed their highly anticipated fund with the projected $4.6 billion all in.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

Biogen is stepping out onto the high wire today, reporting that the team working on the controversial Alzheimer’s drug aducanumab has now completed their submission to the FDA. And they want the agency to bless it with a priority review that would cut the agency’s decision-making time to a mere 6 months.

The news drove a 10% spike in Biogen’s stock $BIIB ahead of the bell.

Part of that spike can be attributed to a relief rally. Biogen execs rattled backers and a host of analysts earlier in the year when they unexpectedly delayed their filing to the third quarter. That delay provoked all manner of speculation after CEO Michel Vounatsos and R&D chief Al Sandrock failed to persuade influential observers that the pandemic and other factors had slowed the timeline for filing. Actually making the pitch at least satisfies skeptics that the FDA was not likely pushing back as Biogen was pushing in. From the start, Biogen execs claimed that they were doing everything in cooperation with the FDA, saying that regulators had signaled their interest in reviewing the submission.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

It’s a race to the Phase III finish line now for the 2 leading mRNA vaccines in the pipeline for Covid-19.

BioNTech chief Ugur Sahin told the Wall Street Journal that his company will start Phase III testing of their vaccine later this month, setting them up to lateral the data to regulators before the end of this year.

That puts them essentially on the exact same schedule as Moderna is dedicated to. The Massachusetts rival to BioNTech also expects to launch Phase III this month. Lots of rumors have circulated about delays and conflict among the scientists advancing the Moderna jab, but the biotech has consistently stuck to its plan to start a late-stage pivotal this month.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

The US government is on a spending spree. And after committing billions to vaccines defense operations are now doling out more of the big bucks through Operation Warp Speed to back a rapid flip of a drug into the market to stop Covid-19 from ravaging patients — possibly inside of 2 months.

The beneficiary this morning is Regeneron, the big biotech engaged in a frenzied race to develop an antibody cocktail called REGN-COV2 that just started a late-stage program to prove its worth in fighting the virus. BARDA and the Department of Defense are awarding Regeneron a $450 million contract to cover bulk delivery of the cocktail starting as early as late summer, with money added for fill/finish and storage activities.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

Andrew Kruegel was six years into his chemistry work at Columbia University, when, one day in August 2016, he learned he might have only 30 days before the government made him destroy his research.

Kruegel had been studying kratom, a leaf long used in Southeast Asia as a stimulant or for pain. It had opioid-like properties, he found, but seemed to offer pain relief without the addictive potential or respiratory side effects of traditional opioids — a riddle that might help illuminate how human opioid receptors work.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

Over the last generation of drug R&D, Ed Engleman has been a standout scientist.

The Stanford professor co-founded Dendreon and provided the scientific insights needed to develop Provenge into a pioneering — though not particularly marketable — immunotherapy. He’s spurred a slate of startups, assisted by his well-connected perch as a co-founder of Vivo Capital, and took the dendritic cell story into its next chapter at a startup called Bolt.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN